D2 and 5HT2A receptor occupancy of different doses of quetiapine in schizophrenia:: a PET study

被引:103
作者
Gefvert, O [1 ]
Lundberg, T
Wieselgren, IM
Bergström, M
Långström, B
Wiesel, FA
Lindström, L
机构
[1] Cent Hosp, Dept Psychiat Res, S-72189 Vasteras, Sweden
[2] Uppsala Univ, Dept Neurosci, Uppsala, Sweden
[3] Uppsala Univ, PET Ctr, Uppsala, Sweden
关键词
quetiapine; schizophrenic; patients; PET; dopamine D-2 receptors; serotonin 5HT(2A) receptors; atypical antipsychotic;
D O I
10.1016/S0924-977X(00)00133-4
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: Quetiapine is a novel antipsychotic agent with many atypical features, including low D-2 and higher 5HT(2A) affinity in vitro, low propensity to induce extra-pyramidal side effects and minimal effects on prolactin levels. The purpose of this study was to investigate, using position emission tomography (PET), the relationship between plasma concentrations of different doses of quetiapine and occupancy of D-2 and 5HT(2A) receptors in schizophrenic patients, Methods: Five patients were treated with quetiapine (titrated to 750 or 450 mg/day) for 28 days, subsequently reduced weekly in a descending-dose schedule. Dopamine D-2 and 5HT(2A) occupancies were determined using [C-11] raclopride and [C-11] N-methylspiperone as ligands, respectively, and PET imaging. Results: Mean D, receptor occupancies of 41 and 30%, were observed at quetiapine doses of 750 and 450 mg/day. At lower dose levels no occupancy could be determined. Quetiapine: induced a consistently higher degree of 5HT(2A) receptor occupancy, with mean occupancies of 74 and 57% at doses of 750 anti 450 mg/day, respectively. No EPS emerged during the trial and most of the pre-trial EPS resolved during the study. Conclusions: In clinically effective doses, quetiapine induced low occupancy at D-2 receptors, which is consistent with atypical antipsychotics such as clozapine. and probably explains the lack of EPS observed in this trial. Correlations between receptor occupancy and plasma concentrations of quetiapine could not he calculated, although receptor occupancy increased with higher plasma concentrations for the 450 and 750 mg doses. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:105 / 110
页数:6
相关论文
共 33 条
  • [1] ANDERSSON JLR, 1995, J NUCL MED, V36, P657
  • [2] Multiple fixed doses of ''Seroquel'' (quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo
    Arvanitis, LA
    Miller, BG
    Borison, RL
    Pitts, WM
    Sharif, ZA
    Hamner, MB
    Herz, MI
    True, JE
    Velligan, D
    Knesevich, MA
    Small, J
    Steinbook, R
    Hertzman, M
    Keck, PE
    Newcomer, JW
    Grace, J
    Rotrosen, J
    Tandon, R
    Dott, SG
    Ferguson, JM
    Addington, DEN
    MacEwan, GW
    Nair, VNP
    Shriqui, CL
    Williams, R
    Daniel, DG
    Shehi, GM
    Patterson, WM
    Merideth, CH
    [J]. BIOLOGICAL PSYCHIATRY, 1997, 42 (04) : 233 - 246
  • [3] DOSE-DEPENDENT OCCUPANCY OF CENTRAL DOPAMINE-D(2) RECEPTORS BY THE NOVEL NEUROLEPTIC CP-88,059-01 - A STUDY USING POSITRON EMISSION TOMOGRAPHY AND C-11 RACLOPRIDE
    BENCH, CJ
    LAMMERTSMA, AA
    DOLAN, RJ
    GRASBY, PM
    WARRINGTON, SJ
    GUNN, K
    CUDDIGAN, M
    TURTON, DJ
    OSMAN, S
    FRACKOWIAK, RSJ
    [J]. PSYCHOPHARMACOLOGY, 1993, 112 (2-3) : 308 - 314
  • [4] ICI 204,636, an atypical antipsychotic: Efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia
    Borison, RL
    Arvanitis, LA
    Miller, BG
    Alphs, LD
    Carman, JS
    Diamond, B
    Gewirtz, G
    Hamner, MB
    Hirshfield, R
    McEvoy, JP
    Mukherjee, S
    Nasrallah, HA
    Oxenkrug, G
    Ryan, W
    Smith, N
    Tamminga, C
    [J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1996, 16 (02) : 158 - 169
  • [5] Davis PC, 1999, J PHARMACEUT BIOMED, V20, P271
  • [6] SUPERSENSITIVITY PSYCHOSIS IN SCHIZOPHRENIC-PATIENTS AFTER SUDDEN CLOZAPINE WITHDRAWAL
    EKBLOM, B
    ERIKSSON, K
    LINDSTROM, LH
    [J]. PSYCHOPHARMACOLOGY, 1984, 83 (03) : 293 - 294
  • [7] KINETIC-ANALYSIS OF CENTRAL [C-11] RACLOPRIDE BINDING TO D2-DOPAMINE RECEPTORS STUDIED BY PET - A COMPARISON TO THE EQUILIBRIUM-ANALYSIS
    FARDE, L
    ERIKSSON, L
    BLOMQUIST, G
    HALLDIN, C
    [J]. JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 1989, 9 (05) : 696 - 708
  • [8] Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel®) in patients with schizophrenia
    Gefvert, O
    Bergström, M
    Långström, B
    Lundberg, T
    Lindström, L
    Yates, R
    [J]. PSYCHOPHARMACOLOGY, 1998, 135 (02) : 119 - 126
  • [9] N-[11C]methylspiperone PET, in contrast to [11C]raclopride, fails to detect D2 receptor occupancy by an atypical neuroleptic
    Hagberg, G
    Gefvert, O
    Bergström, M
    Wieselgren, IM
    Lindström, L
    Wiesel, FA
    Långström, B
    [J]. PSYCHIATRY RESEARCH-NEUROIMAGING, 1998, 82 (03) : 147 - 160
  • [10] RECEPTOR-BINDING OF N-(METHYL-C-11) CLOZAPINE IN THE BRAIN OF RHESUS-MONKEY STUDIED BY POSITRON EMISSION TOMOGRAPHY (PET)
    HARTVIG, P
    ECKERNAS, SA
    LINDSTROM, L
    EKBLOM, B
    BONDESSON, U
    LUNDQVIST, H
    HALLDIN, C
    NAGREN, K
    LANGSTROM, B
    [J]. PSYCHOPHARMACOLOGY, 1986, 89 (02) : 248 - 252